Chicago Atlantic Real Estate Finance, Inc. (REFI) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects stable financial performance with a slight increase in distributable earnings and book value per share. However, the Q&A reveals uncertainties in pipeline timing and market competition, along with challenges in Arizona. Despite a 50% increase in the pipeline, no pricing changes are noted. The company's conservative approach to loan #9 and stable CECL reserve suggest cautious optimism. Overall, the mixed signals and lack of clear guidance lead to a neutral sentiment.
Key Financial Performance
Loan Portfolio Principal $411 million across 26 portfolio companies as of December 31, 2025, with a weighted average yield to maturity of 16.3%, compared to 16.5% in the third quarter. The slight decrease in yield was due to the impact of multiple benchmark prime rate cuts in the fourth quarter totaling 50 basis points.
Gross Originations $19 million of principal fundings during the fourth quarter, with $5 million advanced to a new borrower and $14 million to existing borrowers. This reflects the company's ongoing efforts to expand its loan portfolio.
Net Interest Income $14.2 million for the fourth quarter, a 4% increase from $13.7 million in the third quarter of 2025. The increase was primarily due to the collection of past due accrued interest on loan #9, totaling $1.7 million, offset by the impact of prime rate cuts.
Total Leverage 32% of book equity as of December 31, 2025, compared to 33% as of September 30, 2025. This slight decrease indicates improved leverage management.
Interest Expense $1.8 million for the fourth quarter, up from $1.6 million in the third quarter. The increase was due to higher weighted average borrowings on the revolving loan, which rose to $33.6 million from $14 million in the third quarter.
CECL Reserve $5.1 million as of December 31, 2025, representing 1.23% of the outstanding principal of loans held for investment. This remained consistent with the prior quarter, reflecting stable credit quality.
Loan-to-Enterprise Value Ratio 44.2% as of December 31, 2025, calculated as senior indebtedness of the borrower divided by the fair value of total collateral. This indicates strong collateral coverage.
Distributable Earnings Per Share $0.44 (basic) and $0.43 (fully diluted) for the fourth quarter, and $1.92 (basic) and $1.88 (fully diluted) for the year. This reflects the company's ability to generate consistent earnings for shareholders.
Book Value Per Common Share $14.60 as of December 31, 2025, reflecting the company's financial stability and shareholder equity.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Credit facility for cannabis ESOP: Closed on a credit facility to support the largest cannabis ESOP completed to date, showcasing innovative financial solutions in the cannabis lending market.
Cannabis policy changes: Positive momentum in cannabis policy with bills introduced in several states and an executive order to reclassify cannabis from Schedule I to Schedule III, potentially improving industry economics.
Loan portfolio performance: Loan portfolio principal totaled $411 million across 26 companies with a weighted average yield to maturity of 16.3%. Gross originations were $19 million, with $5 million to a new borrower and $14 million to existing borrowers.
Interest rate protection: 91% of the loan portfolio is protected from rate declines through fixed rates or rate floors, minimizing exposure to interest rate volatility.
Loan repayment and advances: Advanced $51.1 million in new loans and received $40.4 million in repayments in early 2026, maintaining strong liquidity.
Focus on cannabis lending: Maintains a disciplined focus on cannabis lending with limited competition, leveraging sector expertise and a strong underwriting team to create a differentiated risk-return profile.
Pipeline expansion: Strong pipeline of $616 million, with first looks at major opportunities in the cannabis sector, indicating growth potential.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Interest Rate Volatility: The company has structured its floating rate loans with high interest rate floors and no caps, which limits exposure to further rate declines. However, 9% of the loan portfolio remains exposed to rate declines, which could impact net investment income.
Loan Performance Risk: Loan #9 remains on nonaccrual status despite being brought current, indicating potential ongoing performance risks. The loan will only be restored to accrual status after sustained performance and timely debt service payments.
Regulatory and Policy Risks: While there has been positive momentum in cannabis policy, including reclassification of cannabis from Schedule I to Schedule III, the company’s strategy assumes no regulatory-driven credit improvements. Any adverse regulatory changes could impact the cannabis sector and the company’s operations.
Economic and Market Conditions: The company operates in a niche market with limited lending competition, but broader economic uncertainties or changes in market conditions could impact the pipeline and borrower performance.
Credit Quality and Reserve Levels: The company maintains a CECL reserve of $5.1 million, representing 1.23% of outstanding loan principal. While this reserve is consistent with prior quarters, any unexpected borrower defaults could strain this reserve.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Pipeline and Lending Opportunities: The pipeline remains strong at $616 million, with first looks at the largest opportunities within the cannabis sector. The company is also leading in providing creative financial solutions, such as the credit facility for the largest cannabis ESOP to date.
Cannabis Policy Developments: Recent positive momentum in cannabis policy, including an executive order to reclassify cannabis from Schedule I to Schedule III, is expected to improve industry economics without increasing lending competition. However, the company's strategy does not rely on regulatory-driven credit improvements.
Interest Rate Exposure: Only 9% of the loan portfolio is exposed to further rate declines due to high interest rate floors and no caps on floating rate loans. A hypothetical 100 basis point decline in benchmark rates would result in a minimal $14,000 decrease in net investment income, while a 200 basis point decline would increase net investment income.
Loan Portfolio and Growth: As of December 31, 2025, the loan portfolio totaled $411 million across 26 companies, with a weighted average yield to maturity of 16.3%. Gross originations during the quarter were $19 million, and significant progress was made on specific loans, such as funding for additional dispensaries in Pennsylvania.
Dividend and Earnings Outlook: The company expects to maintain a dividend payout ratio of 90% to 100% for the 2026 tax year, with potential for a special dividend in the fourth quarter if taxable income requires additional distributions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Fourth Quarter Dividend: $0.47 per common share declared by the Board in December and distributed in January.
Annualized Yield on Cost: Approximately 12.4% when measured against the IPO price.
Total Dividends Since Inception: $8.47 per common share.
Dividend Payout Ratio for 2026: Expected to maintain a ratio of 90% to 100% of basic distributable earnings per share.
Special Dividend: May be issued in the fourth quarter if taxable income requires additional distributions.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide some general line of sight as to when some of the originations in the pipeline might come to fruition and how many are at the later stage of being finalized?
A:Management is targeting net portfolio growth for the year and has confidence in executing the pipeline. They have $50 million of liquidity available as of March 12, which can be deployed quickly. However, the timing of repayments in the portfolio by December 31 is uncertain and difficult to forecast.
Q:What is the outlook in terms of current yields for potential deals in the pipeline, and has rescheduling impacted rate negotiations or the underwriting process?
A:Rescheduling has increased demand for debt capital but has not changed pricing or the underwriting process. Management has not observed new lenders entering the market due to rescheduling.
Q:Is the lack of increased competition in the market as of today, or does it assume Schedule III gets finalized? What would increase competition in the space?
A:As of today, no new lenders have entered the market due to rescheduling. Management believes that full legalization, listing cannabis companies on major stock exchanges, and broader financial ecosystem support would be required to increase competition. These changes would take time to evolve.
Q:Are the two new nonaccrual loans in Arizona related to the same sponsor, or is it something market-specific in Arizona?
A:The two nonaccrual loans are related to the same sponsor. Arizona is facing a challenging pricing environment, and the borrower is navigating this in close collaboration with management.
Q:Why did you decide to lend more money to a borrower in trouble (loan #9), and can you provide more color on the situation?
A:Loan #9 underwent a full foreclosure, change of control, and recapitalization in 2025. The borrower reorganized operations, improved cash flow and revenue, and became current on interest payments by the end of 2025. Management remains conservative in presenting the loan as nonaccrual despite its current status.
Q:Can you provide color on the early repayments for loan #1 and loan #27?
A:Loan #1 was refinanced with a new credit facility in which Chicago Atlantic participated. Loan #27 was paid off, and management opted not to pursue refinancing due to pricing and credit-related decisions. Management views this as a healthy mix of refinancing and extensions.
Q:How do you reconcile the pipeline increasing by 50% while stating no changes in pricing or risk evaluation due to rescheduling?
A:The pipeline reflects a broad range of risk-reward opportunities. As capital becomes constrained, selection and funding decisions are adjusted. Rescheduling has not led to changes in underwriting standards, leverage, or pricing.
Q:What is your response to the argument that rescheduling may not significantly impact cash flow or equity issuance for cannabis companies?
A:Management disagrees, emphasizing that unpaid 280E taxes are unsustainable and factored into underwriting. Rescheduling would eliminate these taxes, representing a strong credit improvement.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the timing of originations in the pipeline and the specifics of what would increase competition in the cannabis market. Additionally, their response to the argument about rescheduling's impact on cash flow and equity issuance lacked detailed evidence to counter the claim.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Atlantic Real
Chicago Atlantic
Estate Finance
Real Estate
SEC
advance
basis point
borrower loan
cannabis
capability
capital
credit estate
credit facility
dispensary
equity
expertise
exposure
industry
interest rate
investment income
lending competition
lending market
loan rate
maturity
measure
origination
point decline
portfolio rate
rate decline
rate floor
rate loan
sector
slide
yield
REFI Transcript
Chicago Atlantic Real Estate Finance, Inc. (REFI) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call summary reflects stable financial performance with a slight increase in distributable earnings and book value per share. However, the Q&A reveals uncertainties in pipeline timing and market competition, along with challenges in Arizona. Despite a 50% increase in the pipeline, no pricing changes are noted. The company's conservative approach to loan #9 and stable CECL reserve suggest cautious optimism. Overall, the mixed signals and lack of clear guidance lead to a neutral sentiment.
5N Plus Inc. (VNP:CA) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call presents a positive outlook with strong financial performance, including reduced net debt and high gross margins. Although Q4 guidance indicates a temporary EBITDA decline, optimistic growth in the cannabis pipeline and strategic credit facility extensions support long-term growth. The Q&A reveals no significant supply chain issues and expectations of future margin tailwinds, despite management's vague response on gross margins. The positive sentiment outweighs concerns, indicating a likely positive stock price movement.
Pet Valu Holdings Ltd. (PET:CA) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call summary indicates positive developments, such as increased cannabis pipeline, credit facility extension, and dividend payout expectations. Despite some uncertainties in the Q&A, the company's strategic plans and financial health appear robust. The positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.
Chicago Atlantic Real Estate Finance, Inc. (REFI) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call presents a mixed picture: while the cannabis pipeline growth and credit facility extension are positives, the decrease in net interest income and distributable earnings per share are negatives. The Q&A section reveals management's cautious approach but lacks clarity on specific financial impacts. No new partnerships or significant guidance changes were announced, and competition in the cannabis sector is increasing. Given these factors, the stock price is likely to remain stable, leading to a neutral prediction.
REFI Slides
Chicago Atlantic Q4 2025 slides: cannabis REIT highlights 16% yield amid earnings miss2026-03-12
Chicago Atlantic Q3 2025 slides: Cannabis REIT maintains 16.5% yield despite earnings miss2025-11-04
Chicago Atlantic Q2 2025 slides: Cannabis REIT reports improved interest income amid market challenges2025-08-07
Chicago Atlantic Q1 2025 slides: cannabis REIT reports mixed results amid industry challenges2025-05-07
REFI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
